Table 4 Persistent and exercise-induced myocardial perfusion defects in SLE patients from placebo group and atorvastatin group at randomization and after one year of treatment
| Â | At randomization | After one year | P |
|---|---|---|---|
Placebo group, n = 32 | |||
Number of patients with persistent perfusion defects | 14 (43.8%) | 11 (34.3%) | ns |
Number of persistently underperfused segments | 2-5 (median 3) | 3-6 (median 3) | ns |
Number of patients with exercise-induced perfusion defects | 4 (12.5%) | 6 (18.8%) | ns |
Number of underperfused myocardial segments at exercise | 1-4 (median 3) | 2-3 (median 3) | ns |
Atorvastatin group, n = 28 | |||
Number of patients with persistent perfusion defects | 8 (28.6%) | 8 (28.6%) | ns |
Number of persistently underperfused segments | 1-5 (median 3) | 2-6 (median 3) | ns |
Number of patients with exercise-induced perfusion defects | 4 (14.3%) | 5 (17.9%) | ns |
Number of underperfused myocardial segments at exercise | 2-4 (median 3) | 3-6 (median 3) | ns |